

Comp-APC-A

CD32

CD32

0

CD32

Supplementary Fig. 1

Supplementary Figure 1. Gating strategy in the IL-2, PHA/IL-2 and α -CD3/ α -CD28 treated PBMCs or CD4+ T cells from donors. (a) Cell doublets were removed from the analysis (FSC-A versus FSC-H) and lymphocytes were gated by using the forward and side scatter areas (FSC and SSC). Monocytes (upper/right) and B lymphocytes (b) were excluded by labeling CD14 and CD19 cell surface markers. The marginal CD8+ T cell population found after negative selection was excluded and cell activation markers (HLA-DR and CD69) were measured in the CD4+ population in combination with CD32. Dot plots from a representative donor are shown.



Supplementary Figure 2. mRNA expression of FGCR2a (CD32a) in stimulated CD4+ T cells. CD32 gene expression levels in purified CD4+ T cells after activation with IL-2 or PHA and IL-2. Relative mRNA expression of FGCR2a was measured using quantitative PCR and normalized to GAPDH expression. The data represent $1/\Delta$ Ct*100.





Supplementary Figure 5.



Supplementary Figure 5. CD32 staining in HIV-1 infected individuals. Individual dot plots from the 23 HIV-1+ subjects evaluated, showing CD32 staining in previously gated CD4+ T cells. Individual isotype control labeling was set to a stringent criteria (less or equal to 0.1% positive cells).